Inclusion Criteria:

- Written informed consent

- Caucasian female postmenopausal patients

- Patients with histologically confirmed primary palpable and nonpalpable breast
cancer sized up to 5 cm (T1 - T2)

Exclusion Criteria:

- Suspicious lymphogenic metastases (cN1-3)

- Acute or chronic hepatic diseases

- Manifest renal diseases with renal dysfunction

- Relevant cardiac disease

- Preceding therapy of breast tumour under investigation

- Patients with multiple attempts of hook-wire placement in preparation of surgery

- Dementia or psychic condition that might interfere with the ability to understand the
study and thus give a written informed consent

- Simultaneous participation in another clinical study or participation in another
clinical study in the 30 days directly preceding treatment